You are here

  • Home
  • Archive
  • Volume 27, Issue 3
  • When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

Article Text

Article menu
Download PDFPDF
EBM opinion and debate
When we move cancer drugs from the second or third to the first line of treatment: what lessons can we learn from KEYNOTE-177 and JAVELIN-100

https://doi.org/10.1136/bmjebm-2021-111702

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Contributors VP developed the concept of the paper and provided critical revision. MSK drafted the paper. Both authors approved the final paper and are accountable for all aspects of the work.

    • Funding VP was funded by Arnold Ventures.

    • Competing interests VP discloses: Research funding from Arnold Ventures, royalties from Johns Hopkins Press, Medscape and MedPage, consulting fees from UnitedHealthcare, speaking fees from eviCore and New Century Health and other (Plenary Session podcast has Patreon backers).

    • Provenance and peer review Not commissioned; externally peer reviewed.